Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Allosteric therapy targets common genetic cause of Parkinson’
Drug Discovery World
Related Posts
Post navigation
Previous Post
Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287
Next Post
The Potential of Neurofilament Light Chain as a Biomarker in Parkinson’s Disease
Latest Articles
Clear Filters
March 21, 2023
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
Read More
May 17, 2021
Gain Therapeutics to Participate in Upcoming Virtual Investor Conferences in May
Read More
September 13, 2021
Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s
Read More
Close